A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension.
Phase of Trial: Phase III
Latest Information Update: 29 May 2013
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov
- 20 Nov 2008 Planned end date changed from 1 Feb 2008 to 1 Feb 2009, reported by ClinicalTrials.gov.